+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Global Genetic Testing Market - Forecasts from 2018 to 2023

  • ID: 4479424
  • Report
  • Region: Global
  • 95 pages
  • Knowledge Sourcing Intelligence LLP
until Dec 31st 2019
1 of 3


  • 23andMe,Inc.
  • Abbot
  • Ariosa Diagnostic, Inc.
  • AutoGenomics
  • Biocartis
  • Cepheid
  • MORE
The global genetic testing market was valued at US$5.060 billion in 2018 and is projected to expand at a CAGR of 12.94% over the forecast period to reach US$9.296 billion by 2023. Genetic testing is carrying out the range of tests on the sample of DNA derived from blood, saliva, skin, and other tissues. Genetic tests are majorly conducted for diagnosing genetic disorders, identifying the mutation in the gene, and designing the treatment package. The growing prevalence of genetic disorders has been instrumental in driving the market. Moreover, the reduction in the genetic testing prices has increased the number of individual undergoing genetic test since it has a scope beyond the medical field because of its ability to provide the ancestral history about an individual. However, concerns regarding the confidentiality and misleading advice along with the difficulty in interpreting the result has limited the market growth.

By Type:
The global genetic testing market is segmented as prenatal testing, newborn screening, diagnostic testing, carrier testing, and predictive & pre-symptomatic testing. The continuous technological advancement has made prenatal testing relatively affordable and gives more accurate results which is driving the market for prenatal testing. In February 2018, the Becton, Dickinson and Company has announced the commercial availability of PAXgene® Blood ccfDNA tube within the European Economic Area and Switzerland which has been designed to ensure accurate and reproducible results in molecular diagnostic testing applications circulating cell-free DNA. Newborn screening is conducted to identify the genetic disorders that have the possibility of being treated in the initial years. In the United States, it is recommended to get a newborn screening test that checks for a minimum of 34 disorders. In February 2018, Sema4 launched supplemental newborn screening test ‘Sema4 Natalis’ which is designed to detect 193 childhood-onset diseases or disorders. Moreover, there is a growing prevalence of depression among women globally which increases the possibility of defected birth. Thus, the growing prevalence of depression among women is driving the genetic testing market for newborn screening.

By Disease:
By disease, the genetic testing market is segmented as cancer, cystic fibrosis, sickle cell anemia, Duchenne muscular dystrophy, Alzheimer disease, thalassemia, huntington disease, and others. Cancer is one of the leading causes of mortality and morbidity globally and was responsible for 8.8 million deaths in 2015. Approximately 5%-10% of all the cancers are caused by inheriting genetic mutation. The growing prevalence of cancers is leading to significant increase in the number of the genetic test conducted for testing cancer. Cystic fibrosis is a genetic disorder that affects the respiratory, digestive, and reproductive system involving the production of abnormally thick mucus lining in the lungs. The disease is more prevalent in North America, Europe, and Australasia.

By Technology:
The global genetic testing market is segmented as cytogenetic testing, biochemical testing, and molecular testing based on technology. Cytogenetic testing is conducted to detect the abnormalities in the chromosome structure. There is a growing prevalence of chromosome abnormally related diseases such down syndrome, Edwards-syndrome, and growth disorders among others. Biochemical testing study the amount or activity level of protein to determine the abnormality that indicate the changes in the DNA which results in a genetic disorder. The abnormality in protein can lead to birth defects in children which is leading to increasing number of newborn screening test being conducted globally.

By Geography:

The global genetic testing market is segmented as North America, South America, Europe, Middle East and Africa, and Asia Pacific. The regions are further analyzed on the basis of countries. The recent regulatory support for the direct to consumer genetic testing along with the increasing insurance coverage and reduction in the cost of genetic test is anticipated to lead to the growth of genetic testing market in the United States. Simultaneously, in Canada, the growing prevalence of genetic diseases in along with the lack of ‘stringent’ regulations, more specifically for the direct-to-consumers genetic test, will lead to the growth of the market, however, the recent bill passed by the parliament is likely to check the growth as it provides individuals a choice for getting themselves genetically tested in order to gain employment or any commercial concerns.

Competitive landscape:
The global genetic testing market is competitive owing to the presence of well diversified international and regional players. The competitive landscape details strategies, products, and investments being done by key players in different technologies and companies to boost their market presence.

Major industry players profiled as part of the report are Abbot, Precipio Inc., Ariosa Diagnositic Inc., and Sequenom Inc.


The global genetic testing market has been analyzed through following segments:
By Type:
  • Prenatal Testing
  • Newborn Screening
  • Diagnostic Screening
  • Carrier Testing
  • Predictive & Pre-symptomatic Testing
  • By Disease
  • Cancer
  • Cystic Fibrosis
  • Sickle Cell Anemia
  • Duchenne Muscular Dystrophy
  • Alzheimer Disease
  • Thalassemia
  • Huntington Disease
  • Others
  • By Technology
  • Cytogenetic testing
  • Biochemical Testing
  • Molecular Testing
By Geography:
  • North America
  • United States
  • Canada
  • Mexico
  • Others
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
  • Middle East and Africa
  • Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Others
Note: Product cover images may vary from those shown
2 of 3


  • 23andMe,Inc.
  • Abbot
  • Ariosa Diagnostic, Inc.
  • AutoGenomics
  • Biocartis
  • Cepheid
  • MORE
1. Introduction
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline

2. Research Methodology
2.1. Research Design
2.2. Secondary Sources


4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter’s Five Force Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Product Pipeline
4.7. Life Cycle Analysis - Regional Snapshot
4.8. Market Attractiveness

5.1. Prenatal Testing
5.2. Newborn Screening
5.3. Diagnostic Testing
5.4. Carrier Testing
5.5. Predictive & Presymptomatic Testing

6.1. Cancer
6.2. Cystic Fibrosis
6.3. Sickle Cell Anemia
6.4. Duchenne Muscular Dystrophy
6.5. Alzheimer Disease
6.6. Thalassemia
6.7. Huntington Disease
6.8. Others

7.1. Cytogenetic Testing
7.2. Biochemical Testing
7.3. Molecular Testing

8.1. North America
8.1.1. United States
8.1.2. Canada
8.1.3. Mexico
8.1.4. Others
8.2. South America
8.2.1. Brazil
8.2.2. Argentina
8.2.3. Others
8.3. Europe
8.3.1. United Kingdom
8.3.2. Germany
8.3.3. France
8.3.4. Italy
8.3.5. Others
8.4. Middle East and Africa
8.5. Asia Pacific
8.5.1. Japan
8.5.2. China
8.5.3. India
8.5.4. Australia
8.5.5. Others

9.1. Market Share Analysis
9.2. Recent Deals and Investment
9.3. Strategies of Key Players

10.1. F.Hoffmann-La Roche Ltd
10.1.1. Company Overview
10.1.2. Financials
10.1.3. Products and Services
10.1.4. Recent Developments
10.2. Abbot
10.2.1. Company Overview
10.2.2. Financials
10.2.3. Products and Services
10.2.4. Recent Developments
10.3. Pecipio Inc.
10.3.1. Company Overview
10.3.2. Financials
10.3.3. Products and Services
10.3.4. Recent Developments
10.4. Ariosa Diagnostic Inc.
10.4.1. Company Overview
10.4.2. Financials
10.4.3. Products and Services
10.4.4. Recent Developments
10.5. Biocartis
10.5.1. Company Overview
10.5.2. Financials
10.5.3. Products and Services
10.5.4. Recent Developments
10.6. Cepheid
10.6.1. Company Overview
10.6.2. Financials
10.6.3. Products and Services
10.6.4. Recent Developments
10.7. 23andMe, Inc.
10.7.1. Company Overview
10.7.2. Financials
10.7.3. Products and Services
10.7.4. Recent Developments
10.8. Luminex Corporation
10.8.1. Company Overview
10.8.2. Financials
10.8.3. Products and Services
10.8.4. Recent Developments
10.9. Sequenom, Inc.
10.9.1. Company Overview
10.9.2. Financials
10.9.3. Products and Services
10.9.4. Recent Developments
10.10. AutoGenomics
10.10.1. Company Overview
10.10.2. Financials
10.10.3. Products and Services
10.10.4. Recent Developments
10.11. Illumina, Inc.
10.11.1. Company Overview
10.11.2. Financials
10.11.3. Products and Services
10.11.4. Recent Developments
Note: Product cover images may vary from those shown
3 of 3


4 of 3
  • F.Hoffmann-La Roche Ltd
  • Abbot
  • Precipio Inc.
  • Ariosa Diagnostic, Inc.
  • Biocartis
  • Cepheid
  • 23andMe,Inc.
  • Luminex Corporation
  • Sequenom, Inc.
  • AutoGenomics
  • Illumina, Inc.
Note: Product cover images may vary from those shown